Gastric emptying and tachyphylaxis: why the slowing fades

The stomach is where these drugs make themselves felt first. It is also where the effect wears off fastest, and the reason for that tells you something about the whole drug class.

How GLP-1 slows the stomach

GLP-1 receptor activation slows gastric emptying mainly through the vagus nerve: afferent signals from the gut and receptors in the brainstem reduce the motor output that drives the antrum and relaxes the pylorus. The result is that a meal leaves the stomach more slowly, glucose enters the small intestine more gradually, and the post-meal glucose peak is lower and later. This was the original explanation for the drug class's effect on post-meal glucose, and for short-acting agents like exenatide it remains the dominant one.

The fading, measured

In 2011 Nauck and colleagues infused GLP-1 continuously into healthy volunteers across two consecutive test meals. The slowing of emptying during the first meal was large. During the second meal, a few hours later, most of it was gone (PubMed 21430088). That is tachyphylaxis: a diminishing response to a continuously present stimulus. Umapathysivam and colleagues then compared prolonged and intermittent GLP-1 exposure and found that intermittent stimulation preserved the gastric effect while prolonged stimulation lost it (PubMed 24089511). The receptor is not disappearing; the vagal circuit is adapting.

Long-acting drugs are, by design, continuous stimulation. Urva and colleagues measured gastric emptying with an acetaminophen absorption test in a phase 1 tirzepatide study: the delay was greatest after the first dose and had largely diminished by week 4, a pattern the paper describes as similar to selective long-acting GLP-1 receptor agonists (PubMed 32519795). The Zepbound label puts it the same way, noting the delay is greatest after the first dose and diminishes over time. For semaglutide at steady state, Hjerpsted and colleagues found first-hour emptying delayed but no difference in overall 5-hour emptying versus placebo (PubMed 28941314).

Why it matters

Post-meal glucose. For long-acting drugs, the durable glucose effect comes from insulin and glucagon changes rather than from the stomach, because the stomach effect fades. Short-acting agents that are dosed around meals keep more of the gastric effect.

Nausea. The early peak in gastric slowing lines up with the early peak in nausea, and both decline together, which is one reason the nausea page treats the stomach as part of the story but not all of it.

Oral medicines. The labels warn that delayed emptying can change how quickly other oral drugs are absorbed, with the biggest effect around dose initiation and escalation. The Zepbound label specifically advises people on oral hormonal contraceptives to use a non-oral or barrier method for 4 weeks after starting and after each dose increase.

Procedures. Retained gastric contents despite fasting have been reported in people on these drugs, and the labels now carry a statement about anaesthesia and deep sedation. Tell your care team what you take; do not adjust dosing around a procedure without being told to.

What is debated

Whether tachyphylaxis is complete or partial for each agent at each dose is not settled, because studies use different methods (scintigraphy, breath tests, acetaminophen absorption) that measure different phases of emptying. Hjerpsted's semaglutide data show a persisting first-hour delay at steady state, so "the effect disappears" overstates it. "Shrinks to a small residual effect" is closer to the evidence.

Where to go next

• Dosing arithmetic for escalation steps lives at FormBlends Calculators.
• FormBlends' tirzepatide guide covers what the first weeks feel like: tirzepatide introduction.